Relevant Disclosure is attached.
Awaiting price reaction for this filing.
Fortis Healthcare's Board approved standalone and consolidated audited financial results for Q4 and FY ended March 31, 2025, with the auditor (B S R & Co. LLP) issuing an unmodified opinion. Standalone revenue from operations grew ~22.4% YoY to ₹144,589 lacs, while standalone net profit fell sharply to ₹6,379 lacs (from ₹19,945 lacs) due to a ₹11,514 lacs exceptional loss (impairment of investments in subsidiaries). Q4 standalone results swung to a net loss of ₹4,223 lacs. The Board recommended a final dividend of ₹1 per share (10% of face value) subject to shareholder approval. The auditor flagged 'emphasis of matters' regarding the ongoing SFIO investigation and the Supreme Court/High Court proceedings related to RHT Health Trust transactions. New Secretarial Auditor (M/s Neelam Gupta & Associates) for 5 years and Cost Auditor (M/s Jitender, Navneet & Co.) for FY26 were also appointed.
Revenue growth is positive, but the headline PAT looks weak because of a non-cash impairment loss on subsidiary investments; underlying operating profit before exceptional items improved meaningfully. The 'emphasis of matter' notes are not qualifications but keep legacy legal/regulatory overhangs on the stock visible. A modest dividend signals continuity of shareholder returns despite ongoing investigations.